Pegylated magnetic nanocarriers for doxorubicin delivery: A quantitative determination of stealthiness in vitro and in vivo

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 81, Issue 3, 2012, Pages 498-505

  Allard Vannier, E ^a   Cohen Jonathan, S ^a   Gautier, J ^a   Herve Aubert K ^a   Munnier, E ^a   Souce M ^a   Legras, P ^b   Passirani, C ^c   Chourpa, I ^a  

^a UNIVERSITÉ DE TOURS   (France)

^b ANGERS UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ D'ANGERS   (France)

Author keywords

Atomic absorption spectrometry; Blood half life; Doxorubicin; Macrophage uptake; Polyethylene glycol; Superparamagnetic iron oxide nanoparticles (SPIONs)

Indexed keywords

CITRATE SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; CITRIC ACID; DOXORUBICIN; DOXORUBICIN SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE COMPLEX; MACROGOL; MACROGOL 500 SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE COMPLEX; PEGYLATED MAGNETIC NANOCARRIER; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AQUEOUS SOLUTION; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; CIRCULATION; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG UPTAKE; FEMALE; HUMAN; HUMAN TISSUE; HYDROPHILICITY; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MONOCYTE; MOUSE; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PLASMA HALF LIFE; QUANTITATIVE ANALYSIS; SURFACE CHARGE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CITRATES; COMPLEMENT ACTIVATION; DOXORUBICIN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG STABILITY; FEMALE; HALF-LIFE; LIVER; MACROPHAGES; MAGNETITE NANOPARTICLES; MICE; MONOCYTES; PARTICLE SIZE; POLYETHYLENE GLYCOLS; SPECTROPHOTOMETRY, ATOMIC; SPLEEN; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 84863774452     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2012.04.002     Document Type: Article

References (45)

1. C. Alexiou, W. Arnold, R.J. Klein, F.G. Parak, P. Hulin, C. Bergemann, W. Erhardt, S. Wagenpfeil, A.S. Lubbe, Locoregional cancer treatment with magnetic drug targeting, Cancer Res. 60 (2000) 6641-6648.
2. J. Dobson, Cancer therapy: a twist on tumour targeting, Nat. Mater. 9 (2010) 95-96.
3. A.S. Lubbe, C. Bergemann, W. Huhnt, T. Fricke, H. Riess, J.W. Brock, D. Huhn, Preclinical experiences with magnetic drug targeting: tolerance and efficacy, Cancer Res. 56 (1996) 4694-4701. (Pubitemid 26338072)
4. A.S. Lubbe, C. Bergemann, H. Riess, F. Schriever, P. Reichardt, K. Possinger, M. Matthias, B. Dorken, F. Herrmann, R. Gurtler, P. Hohenberger, N. Haas, R. Sohr, B. Sander, A.J. Lemke, D. Ohlendorf, W. Huhnt, D. Huhn, Clinical experiences with magnetic drug targeting: a phase I study with 40-epidoxorubicin in 14 patients with advanced solid tumors, Cancer Res. 56 (1996) 4686-4693. (Pubitemid 26338071)
5. C. Alexiou, R.J. Schmid, R. Jurgons, M. Kremer, G. Wanner, C. Bergemann, E. Huenges, T. Nawroth, W. Arnold, F.G. Parak, Targeting cancer cells: magnetic nanoparticles as drug carriers, Eur. Biophys. J. 35 (2006) 446-450.
6. F.M. Kievit, M. Zhang, Surface engineering of iron oxide nanoparticles for targeted cancer therapy, Acc. Chem. Res. (2011).
7. E. Duguet, S. Vasseur, S. Mornet, G. Goglio, A. Demourgues, J. Portier, F. Grasset, P. Veverka, E. Pollert, Towards a versatile platform based on magnetic nanoparticles for in vivo applications, Bull. Mater. Sci. 29 (2006) 581-586. (Pubitemid 44936650)
8. C. Sun, J.S. Lee, M. Zhang, Magnetic nanoparticles in MR imaging and drug delivery, Adv. Drug Deliv. Rev. 60 (2008) 1252-1265.
9. J. Xie, J. Huang, X. Li, S. Sun, X. Chen, Iron oxide nanoparticle platform for biomedical applications, Curr. Med. Chem. 16 (2009) 1278-1294.
10. C. Chouly, D. Pouliquen, I. Lucet, J.J. Jeune, P. Jallet, Development of superparamagnetic nanoparticles for MRI: effect of particle size, charge and surface nature on biodistribution, J. Microencapsul. 13 (1996) 245-255. (Pubitemid 26149536)
11. A. Vonarbourg, C. Passirani, P. Saulnier, J.P. Benoit, Parameters influencing the stealthiness of colloidal drug delivery systems, Biomaterials 27 (2006) 4356-4373. (Pubitemid 43674179)
12. E. Allemann, P. Gravel, J.C. Leroux, L. Balant, R. Gurny, Kinetics of blood component adsorption on poly(D, L-lactic acid) nanoparticles: evidence of complement C3 component involvement, J. Biomed. Mater. Res. 37 (1997) 229-234. (Pubitemid 27467665)
13. A. Vonarbourg, C. Passirani, P. Saulnier, P. Simard, J.C. Leroux, J.P. Benoit, Evaluation of pegylated lipid nanocapsules versus complement system activation and macrophage uptake, J. Biomed. Mater. Res. A 78 (2006) 620-628. (Pubitemid 44253547)
14. M.A. Dobrovolskaia, P. Aggarwal, J.B. Hall, S.E. McNeil, Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution, Mol. Pharm. 5 (2008) 487-495.
15. S. Laurent, S. Boutry, I. Mahieu, L. Vander Elst, R.N. Muller, Iron oxide based MR contrast agents: from chemistry to cell labeling, Curr. Med. Chem. 16 (2009) 4712-4727.
16. H. Maeda, J. Wu, T. Sawa, Y. Matsumura, K. Hori, Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review, J. Control. Release 65 (2000) 271-284. (Pubitemid 30122932)
17. P.P. Adiseshaiah, J.B. Hall, S.E. McNeil, Nanomaterial standards for efficacy and toxicity assessment, Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2 (2009) 99-112.
18. P. Couvreur, C. Vauthier, Nanotechnology: intelligent design to treat complex disease, Pharm. Res. 23 (2006) 1417-1450. (Pubitemid 43993807)
19. X. Shan, Y. Yuan, C. Liu, X. Tao, Y. Sheng, F. Xu, Influence of PEG chain on the complement activation suppression and longevity in vivo prolongation of the PCL biomedical nanoparticles, Biomed. Microdev. 11 (2009) 1187-1194.
20. A.S. Karakoti, S. Das, S. Thevuthasan, S. Seal, PEGylated inorganic nanoparticles, Angew. Chem. Int. Ed. Engl. 50 (2011) 1980-1994.
21. K. Herve, L. Douziech-Eyrolles, E. Munnier, S. Cohen-Jonathan, M. Souce, H. Marchais, P. Limelette, F. Warmont, M. Saboungi, P. Dubois, I. Chourpa, The development of stable aqueous suspensions of PEGylated SPIONs for biomedical applications, Nanotechnology 19 (2008) 465608. 465607pp.
22. D.P. Lankveld, R.G. Rayavarapu, P. Krystek, A.G. Oomen, H.W. Verharen, T.G. van Leeuwen, W.H. De Jong, S. Manohar, Blood clearance and tissue distribution of PEGylated and non-PEGylated gold nanorods after intravenous administration in rats, Nanomedicine (Lond) 6 (2011) 339-349.
23. R. Gref, M. Luck, P. Quellec, M. Marchand, E. Dellacherie, S. Harnisch, T. Blunk, R.H. Muller, 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption, Colloids Surf. B: Biointerfaces 18 (2000) 301-313. (Pubitemid 30479870)
24. M.T. Peracchia, C. Vauthier, C. Passirani, P. Couvreur, D. Labarre, Complement consumption by poly(ethylene glycol) in different conformations chemically coupled to poly(isobutyl 2-cyanoacrylate) nanoparticles, Life Sci. 61 (1997) 749-761. (Pubitemid 27315736)
25. R.C. Leonard, S. Williams, A. Tulpule, A.M. Levine, S. Oliveros, Improving the therapeutic index of anthracycline chemotherapy: focus on liposomal doxorubicin (Myocet), Breast 18 (2009) 218-224.
26. J. Gautier, E. Munnier, A. Paillard, K. Herve, L. Douziech-Eyrolles, M. Souce, P. Dubois, I. Chourpa, A pharmaceutical study of doxorubicin-loaded PEGylated nanoparticles for magnetic drug targeting, Int. J. Pharm. 423 (2012) 16-25.
27. E. Munnier, S. Cohen-Jonathan, C. Linassier, L. Douziech-Eyrolles, H. Marchais, M. Souce, K. Herve, P. Dubois, I. Chourpa, Novel method of doxorubicin-SPION reversible association for magnetic drug targeting, Int. J. Pharm. 363 (2008) 170-176.
28. M. Hoenig, A. De Kersabiec, Sample preparation steps for analysis by atomic spectroscopy methods: present status, Spectrochim. Acta B 51 (1996) 1297-1307. (Pubitemid 126383955)
29. I. Bohm, Magnetic resonance cell-tracking studies: spectrophotometry- based method for the quantification of cellular iron content after loading with superparamagnetic iron oxide nanoparticles, Mol. Imaging 10 (2011) 270-277.
30. G. McAuley, M. Schrag, S. Barnes, A. Obenaus, A. Dickson, W. Kirsch, In vivo iron quantification in collagenase-induced microbleeds in rat brain, Magn. Reson. Med. (2011).
31. I. Chourpa, L. Douziech-Eyrolles, L. Ngaboni-Okassa, J.F. Fouquenet, S. Cohen-Jonathan, M. Souce, H. Marchais, P. Dubois, Molecular composition of iron oxide nanoparticles, precursors for magnetic drug targeting, as characterized by confocal Raman microspectroscopy, Analyst 130 (2005) 1395-1403. (Pubitemid 41508853)
32. S. Tsuchiya, Y. Kobayashi, Y. Goto, H. Okumura, S. Nakae, T. Konno, K. Tada, Induction of maturation in cultured human monocytic leukemia cells by a phorbol diester, Cancer Res. 42 (1982) 1530-1536. (Pubitemid 12148801)
33. B. Chertok, B.A. Moffat, A.E. David, F. Yu, C. Bergemann, B.D. Ross, V.C. Yang, Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors, Biomaterials 29 (2008) 487-496. (Pubitemid 350100794)
34. M.R. Gittings, D.A. Saville, The determination of hydrodynamic size and zeta potential from electrophoretic mobility and light scattering measurements, Colloids Surf. A: Physicochem. Eng. Aspects 141 (1998) 111-117. (Pubitemid 28332893)
35. A. Shkilnyy, E. Munnier, K. Hervé, M. Soucé, R. Benoît, S. Cohen-Jonathan, P. Limelette, M. Saboungi, P. Dubois, I. Chourpa, Synthesis and evaluation of novel biocompatible superparamagnetic iron oxide nanoparticles as magnetic anticancer drug carrier and fluorescence active label, J. Phys. Chem. C 114 (2010) 5850-5858.
36. C. Fang, B. Shi, Y.Y. Pei, M.H. Hong, J. Wu, H.Z. Chen, In vivo tumor targeting of tumor necrosis factor-alpha-loaded stealth nanoparticles: effect of MePEG molecular weight and particle size, Eur. J. Pharm. Sci. 27 (2006) 27-36. (Pubitemid 41728252)
37. A. Aqil, S. Vasseur, E. Duguet, C. Passirani, J.P. Benoît, A. Roch, R. Müller, R. Jérôme, C. Jérôme, PEO coated magnetic nanoparticles for biomedical application, Eur. Polym. J. 44 (2008) 3191-3199.
38. S. Jain, V. Mishra, P. Singh, P.K. Dubey, D.K. Saraf, S.P. Vyas, RGD-anchored magnetic liposomes for monocytes/neutrophils-mediated brain targeting, Int. J. Pharm. 261 (2003) 43-55. (Pubitemid 36962744)
39. S. Gordon, P.R. Taylor, Monocyte and macrophage heterogeneity, Nat. Rev. Immunol. 5 (2005) 953-964. (Pubitemid 41746764)
40. T.K. Jain, J. Richey, M. Strand, D.L. Leslie-Pelecky, C.A. Flask, V. Labhasetwar, Magnetic nanoparticles with dual functional properties: drug delivery and magnetic resonance imaging, Biomaterials 29 (2008) 4012-4021.
41. H.L. Ma, Y.F. Xu, X.R. Qi, Y. Maitani, T. Nagai, Superparamagnetic iron oxide nanoparticles stabilized by alginate: pharmacokinetics, tissue distribution, and applications in detecting liver cancers, Int. J. Pharm. 354 (2008) 217-226.
42. D. Mishra, M. Sudarshan, A. Chakraborty, Elemental alteration, iron overloading and metallothionein induction in experimental hepatocarcinogenesis: a free radical-mediated process?, Toxicol Lett. 203 (2011) 40-47.
43. H.S. Choi, W. Liu, P. Misra, E. Tanaka, J.P. Zimmer, B. Itty Ipe, M.G. Bawendi, J.V. Frangioni, Renal clearance of quantum dots, Nat. Biotechnol. 25 (2007) 1165-1170. (Pubitemid 47538116)
44. L.T. Chen, L. Weiss, The role of the sinus wall in the passage of erythrocytes through the spleen, Blood 41 (1973) 529-537.
45. D. Hellstern, K. Schulze, B. Schopf, A. Petri-Fink, B. Steitz, S. Kamau, M. Hilbe, S. Koch-Schneidemann, L. Vaughan, M. Hottiger, M. Hofmann, H. Hofmann, B. von Rechenberg, Systemic distribution and elimination of plain and with Cy3.5 functionalized poly(vinyl alcohol) coated superparamagnetic maghemite nanoparticles after intraarticular injection in sheep in vivo, J. Nanosci. Nanotechnol. 6 (2006) 3261-3268. (Pubitemid 44580009)